# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen maintains Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and raises the price targe...
In the coming months, partner GEICAM hopes to complete the remaining SIVs and the Company hopes to visit the remaining sites.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its P...
The company announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, ...
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price t...
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades.
HC Wainwright & Co. analyst Yi Chen reiterates Greenwich LifeSciences (NASDAQ:GLSI) with a Buy and maintains $36 price t...